Literature DB >> 26676755

Injury-Driven Stiffening of the Dermis Expedites Skin Carcinoma Progression.

Venugopal R Mittapalli1, Josef Madl2, Stefanie Löffek1, Dimitra Kiritsi1, Johannes S Kern1, Winfried Römer2, Alexander Nyström1, Leena Bruckner-Tuderman3.   

Abstract

Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic skin fragility disorder characterized by injury-driven blister formation, progressive soft-tissue fibrosis, and a highly elevated risk of early-onset aggressive cutaneous squamous cell carcinoma (cSCC). However, the mechanisms underlying the unusually rapid progression of RDEB to cSCC are unknown. In this study, we investigated the contribution of injury-induced skin alterations to cSCC development by using a genetic model of RDEB and organotypic skin cultures. Analysis of RDEB patient samples suggested that premalignant changes to the dermal microenvironment drive tumor progression, which led us to subject a collagen VII hypomorphic mouse model of RDEB to chemical carcinogenesis. Carcinogen-treated RDEB mice developed invasive tumors phenocopying human RDEB-cSCC, whereas wild-type mice formed papillomas, indicating that the aggressiveness of RDEB-cSCC is mutation-independent. The inherent structural instability of the RDEB dermis, combined with repeated injury, increased the bioavailability of TGFβ, which promoted extracellular matrix production, cross-linking, thickening of dermal fibrils, and tissue stiffening. The biophysically altered dermis increased myofibroblast activity and integrin β1/pFAK/pAKT mechanosignaling in tumor cells, further demonstrating that cSCC progression is governed by pre-existing injury-driven changes in the RDEB tissue microenvironment. Treatment of three-dimensional organotypic RDEB skin cultures with inhibitors of TGFβ signaling, lysyl oxidase, or integrin β1-mediated mechanosignaling reduced or bypassed tissue stiffness and limited tumor cell invasion. Collectively, these findings provide a new mechanism by which RDEB tissue becomes malignant and offer new druggable therapeutic targets to prevent cSCC onset. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 26676755     DOI: 10.1158/0008-5472.CAN-15-1348

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa.

Authors:  Alexander Nyström; Olivier Bornert; Tobias Kühl; Christine Gretzmeier; Kerstin Thriene; Jörn Dengjel; Andrea Pfister-Wartha; Dimitra Kiritsi; Leena Bruckner-Tuderman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-05       Impact factor: 11.205

2.  Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy.

Authors:  Olivier Bornert; Tobias Kühl; Jeroen Bremer; Peter C van den Akker; Anna Mg Pasmooij; Alexander Nyström
Journal:  Mol Ther       Date:  2016-05-09       Impact factor: 11.454

Review 3.  Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.

Authors:  Michael Vanden Oever; Kirk Twaroski; Mark J Osborn; John E Wagner; Jakub Tolar
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

4.  Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.

Authors:  Velina S Atanasova; Celine Pourreyron; Mehdi Farshchian; Michael Lawler; Christian A Brown; Stephen A Watt; Sheila Wright; Michael Warkala; Christina Guttmann-Gruber; Josefina Piñón Hofbauer; Ignacia Fuentes; Marco Prisco; Elham Rashidghamat; Cristina Has; Julio C Salas-Alanis; Francis Palisson; Alain Hovnanian; John A McGrath; Jemima E Mellerio; Johann W Bauer; Andrew P South
Journal:  Clin Cancer Res       Date:  2019-03-07       Impact factor: 12.531

Review 5.  Next generation human skin constructs as advanced tools for drug development.

Authors:  H E Abaci; Zongyou Guo; Yanne Doucet; Joanna Jacków; Angela Christiano
Journal:  Exp Biol Med (Maywood)       Date:  2017-06-07

Review 6.  Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Velina S Atanasova; Qiujie Jiang; Marco Prisco; Christina Gruber; Josefina Piñón Hofbauer; Mei Chen; Cristina Has; Leena Bruckner-Tuderman; John A McGrath; Jouni Uitto; Andrew P South
Journal:  J Invest Dermatol       Date:  2017-05-24       Impact factor: 8.551

7.  Targeting of Cell Surface Proteolysis of Collagen XVII Impedes Squamous Cell Carcinoma Progression.

Authors:  Célimène Galiger; Stefanie Löffek; Marc P Stemmler; Jasmin K Kroeger; Venugopal R Mittapalli; Lisa Fauth; Philipp R Esser; Johannes S Kern; Frank Meiss; Silke Laßmann; Leena Bruckner-Tuderman; Claus-Werner Franzke
Journal:  Mol Ther       Date:  2017-09-27       Impact factor: 11.454

8.  Epidermal ROCK2 induces AKT1/GSK3β/β-catenin, NFκB and dermal tenascin C; but enhanced differentiation and p53/p21 inhibit papilloma.

Authors:  Siti F Masre; Nicola Rath; Michael F Olson; David A Greenhalgh
Journal:  Carcinogenesis       Date:  2020-10-15       Impact factor: 4.944

Review 9.  Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer.

Authors:  Philip C Trackman
Journal:  Expert Opin Ther Targets       Date:  2016-03-03       Impact factor: 6.902

Review 10.  A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy.

Authors:  Payal M Patel; Virginia A Jones; Christy T Behnam; Giovanni Di Zenzo; Kyle T Amber
Journal:  Antibodies (Basel)       Date:  2021-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.